PET and PET/CT with $^{68}$Gallium-Labeled Somatostatin Analogues in Non GEP-NETs Tumors

Martina Sollini, 1 Paola Anna Erba, 2 Alessandro Fraternali, 1 Massimiliano Casali, 1 Maria Liberata Di Paolo, 1 Armando Froio, 1 Andrea Frasoldati, 3 and Annibale Versari 1

1 Nuclear Medicine Unit, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, 42123 Reggio Emilia, Italy
2 Regional Center of Nuclear Medicine, University of Pisa, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, 56125 Pisa, Italy
3 Endocrinology Unit, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, 42123 Reggio Emilia, Italy

Correspondence should be addressed to Martina Sollini; martinasollini@msn.com

Received 31 August 2013; Accepted 30 October 2013; Published 13 February 2014

Abstract

Somatostatin (SST) is a 28-amino-acid cyclic neuropeptide mainly secreted by neurons and endocrine cells. A major interest for SST receptors (SSTR) as target for in vivo diagnostic and therapeutic purposes was born since a series of stable synthetic SST-analogues PET became available, being the native somatostatin non-feasible for clinical use due to the very low metabolic stability. The rationale for the employment of SST-analogues to image cancer is both based on the expression of SSTR by tumor and on the high affinity of these compounds for SSTR. The primary indication of SST-analogues imaging is for neuroendocrine tumors (NETs), which usually express a high density of SSTR, so they can be effectively targeted and visualized with radiolabeled SST-analogues in vivo. Particularly, SST-analogues imaging has been widely employed in gastroenteropancreatic (GEP) NETs. Nevertheless, a variety of tumors other than NETs expresses SSTR thus SST-analogues imaging can also be used in these tumors, particularly if treatment with radiolabeled therapeutic SST-analogues PET is being considered. The aim of this paper is to provide a concise overview of the role of positron emission tomography/computed tomography (PET/CT) with $^{68}$Ga-radiolabeled SST-analogues PET in tumors other than GEP-NETs.

1. Introduction

Scintigraphy with radiolabeled somatostatin (SST) analogues, first labeled with $^{123}$I and subsequently with $^{111}$In and $^{99m}$Tc, has proven useful in diagnosing SST-receptor (SSTR-) positive tumors with a reported detection rate of 50–100% [1–12]. Although SSTR scintigraphy shows high efficacy for whole-body imaging, there are some limitations in organs with higher physiological uptake (e.g., liver) and in terms of detection of small lesions due to the suboptimal physical resolution of the isotopes used [13, 14]. More recently, the development of SST-analogues radiolabeled with $^{68}$Ga for positron emission tomography (PET) imaging such as $^{68}$Ga-DOTA$^0$-Tyr$^3$ octreotide ($^{68}$Ga-DOTATOC, $^{68}$Ga-edotreotide), $^{68}$Ga-DOTA$^0$-$^{113}$In octreotide ($^{68}$Ga-DOTANOC), and $^{68}$Ga-DOTA$^0$-$^{113}$In octreotate ($^{68}$Ga-DOTATATE) has brought clear advantages compared to radiolabeled SST-analogues scintigraphy offering a higher spatial resolution and improving pharmacokinetics [15–17]. Although $^{68}$Ga-DOTATOC, $^{68}$Ga-DOTANOC, and $^{68}$Ga-DOTATATE can all bind to SSTR subtype 2, they have different affinity profiles for the other SSTR subtypes [18]. In particular, $^{68}$Ga-DOTANOC also shows a good affinity for SSTR subtypes 3 and 5, $^{68}$Ga-DOTATOC also binds to SSTR5 (although with lower affinity than DOTANOC), while $^{68}$Ga-DOTATATE has a predominant affinity for SSTR2 [19]. More recently, has been evaluated the $^{68}$Ga-labeled DOTA-lanreotide (DOTALAN) for which has been reported a high affinity to the SSTR subtypes 2–5 [20, 21] although other data confirmed a high affinity only for SSTR subtypes 3 and 5 [22]. The dosimetric data measured for the whole body and for specific organs using $^{68}$Ga-DOTATATE [23] have been published recently. Although the organ doses and effective doses for $^{68}$Ga-DOTATATE, and $^{68}$Ga-DOTATOC are similar (though
68Ga-DOTATOC is slightly lower), the reported dosimetry of 68Ga-DOTANOC is the lowest [23–25]. Importantly, the effective dose per megabecquerel for 68Ga-labeled SST-analogues is approximately 3–5 times lower than for 111In-DTPA-octreotide resulting in an additional advantage of PET tracers compared to radiolabeled SST-analogs scintigraphy [23, 26].

Finally, there was no observed toxicity, immediate or delayed, during the followup (1 year), for 68Ga-DOTATATE demonstrating that this radiopharmaceutical is safe and both organ-specific and effective dose exposures are acceptable [23].

The primary indication of radiolabeled SST-analogue imaging is for neuroendocrine tumors (NETs), a heterogeneous group of neoplasms that arise from endocrine cells within glands (adrenal medulla, pituitary, and parathyroid) or from endocrine islets in thyroid, pancreas, or respiratory/gastrointestinal tract, which usually express a high density of SSTR. However radiolabeled SST-analogue can also be used in the imaging of inflammatory granulomatous and autoimmune conditions as well as non NETs although they cannot be considered as the first-choice functional imaging modality in the management of these patients, except for the determination of SSTR status [27–30]. Table 1 summarizes the different SSTR subtypes expressed by each tumor considered.

The aim of this paper is to provide a concise overview of the role of positron emission tomography/computed tomography (PET/CT) with 68Ga-labeled SST-analogs in tumors other than GEP-NETs (Tables 2 and 3).

### 2. Sympathoadrenal System Tumors

The use of 68Ga-labeled SST-analogue PET and PET/CT paraganglioma (Figure 1) and phaeochromocytoma (Figure 2) remains small, consisting mainly of case reports and small series.

Fanti et al. [31] evaluated the role of 68Ga-DOTANOC in 14 patients with NET including 3 cases of paragangliomas. All paragangliomas were detected with 68Ga-DOTANOC and were strongly positive. Mittal et al. [32] retrospectively evaluated 145 patients including phaeochromocytoma (n = 2) and paraganglioma (n = 3) with 68Ga-DOTATATE PET/CT. PET/CT was positive in only 1 patient affected by paraganglioma. Several authors have reported the higher diagnostic performances of 68Ga-DOTATATE PET/CT compared to 123I-MIBG scintigraphy in paraganglioma and phaeochromocytoma [33–35]. Kroiss et al. [36] reported a higher sensitivity for lesion detection of 68Ga-DOTATOC PET/CT in metastatic paraganglioma patients (n = 6) compared to 123I-MIBG scan (92% and 63%, resp.). More recently, Maurice et al. [37] reported similar results in 15 patients with phaeochromocytoma (n = 9) or paragangliomas (n = 6) evaluated with 68Ga-DOTATATE PET/CT and 123I-MIBG single photon emission computed tomography (SPECT). Utilizing 123I-MIBG scintigraphy as gold standard, 68Ga-DOTATATE had a sensitivity of 80% and a positive predictive value of 62%. The greatest discordance was in head and neck lesions, with the lesions in 4 patients being picked up by 68Ga-DOTATATE and missed by 123I-MIBG. On a per-lesion analysis, 68Ga-DOTATATE was superior to 123I-MIBG in detecting lesions in all anatomical locations (particularly bone lesions). Very recently, Sharma et al. [38] studied 26 patients with known or suspected head and neck paragangliomas by 68Ga-DOTANOC PET/CT and compared PET/CT findings to 123I-MIBG scintigraphy and CT/MRI results. 68Ga-DOTANOC PET/CT was positive in all patients and it was able to detect more lesions (n = 78) compared to 123I-MIBG alone or combined with CT/MRI (n = 30 and n = 53, resp.). 68Ga-DOTANOC PET/CT has also been compared to CT for the evaluation of bone metastases in patients with NET including patients with paraganglioma (n = 5), being more accurate than CT for the early identification of bone lesions [31].

Hofman et al. [39] compared 68Ga-DOTATATE PET/CT to 111In-octreotide imaging (SPECT or SPECT/CT) in a series of oncological patients including phaeochromocytoma (n = 4) in order to identify the management impact of incremental diagnostic information obtained from PET/CT compared with conventional staging. 68Ga-DOTATATE PET/CT provided additional diagnostic information in a large proportion of patients with consequent high management impact. This impact included directing patients to curative surgery by identifying the primary site and directing patients with multiple metastases to systemic therapy.

In conclusion, in case of negative 123I-MIBG scan in patients with a high pretest probability of phaeochromocytoma or paraganglioma, 68Ga-labeled SST-analogues PET or PET/CT should be considered as the next investigation. Additionally, 68Ga-labeled SST-analogues PET/CT should be considered in the staging of patients in whom metastatic spread, particularly to the bone, is suspected.

### 3. Lung Tumors

68Ga-SST-analogues PET and PET/CT have been evaluated in all types of lung tumor (Figures 3 and 4). Hofmann et al. [15] compared the diagnostic values of 111In-octreotide scintigraphy and 68Ga-DOTATOC PET to morphologic imaging in 8 patients with metastatic carcinoid tumors including 2 bronchial carcinoids. 68Ga-DOTATOC PET was superior to 111In-octreotide scintigraphy in the identification of tumor lesions (overall sensitivity of 100% versus 85%). Similarly, Koukourakis et al. [40] used 68Ga-DOTATOC PET to evaluate 15 cases of carcinoid tumors, including 2 cases of pulmonary carcinoids, reporting an overall sensitivity of 92%. Gabrielli et al. [41] used 68Ga-DOTATOC PET to evaluate 84 patients with NET, including 5 patients with bronchial carcinoids, and reported results higher than those obtained with radiolabeled SST-analogs SPECT or CT. Ambrosini et al. [42] compared 68Ga-DOTANOC PET/CT to CT scan in 11 patients with bronchial carcinoids. There were no false-positive findings at PET/CT, and 68Ga-DOTANOC PET/CT detected more lesions than CT (37 versus 21). On a clinical basis,
**Figure 1:** $^{68}$Ga-DOTATOC PET/CT images (MIP, sagittal, axial) in a patient with metastatic paraganglioma.

**Figure 2:** $^{68}$Ga-DOTATOC PET/CT images (MIP, axial) in a patient affected by metastatic phaeochromochytoma.

**Figure 3:** $^{68}$Ga-DOTATATE PET/CT images (MIP, axial) in a case of metastatic atypical lung carcinoid.
| Tumor Type         | SSTR subtypes expression                                                                 | References |
|-------------------|------------------------------------------------------------------------------------------|------------|
| Astrocytoma       | SSTR1, SSTR2, and SSTR3 in variable percentages                                         | [89]       |
| Breast cancer     | All of the five SSTR subtypes (predominantly SSTR2)                                      | [90]       |
| Colorectal cancer | Predominantly SSTR1 followed by SSTR5 and SSTR2                                           | [91]       |
| DTC               | All of the five SSTR subtypes (predominantly SSTR2 and SSTR3)                            | [92]       |
| Ependymoma        | Commonly SSTR1 or SSTR5                                                                   | [92]       |
| Gastric carcinoma | Commonly SSTR2 and SSTR5, although SSTR3 is detected in several cases                    | [93]       |
| GBM               | Mainly SSTR3 followed by SSTR2 and SSTR1                                                | [89]       |
| GEP-NET           | Predominantly SSTR1 and SSTR2 although SSTR5 is also often detected                      | [94]       |
| GIST              | All of the five SSTR subtypes in variable percentages                                     | [95, 96]   |
| HCC               | Mainly SSTR5, although SSTR1, SSTR2, and SSTR3 are also often detected                   | [97]       |
| Lymphoma          | Mainly SSTR2 and SSTR3                                                                    | [98]       |
| Medulloblastoma    | Mainly SSTR2                                                                             | [94]       |
| Melanoma          | All of the five SSTR subtypes (predominantly SSTR1)                                      | [99]       |
| Meningioma        | All of the five SSTR subtypes (predominantly SSTR1 and SSTR2)                            | [100]      |
| Merkel cell carcinoma | Mainly SSTR2  |                                                                 | [101]      |
| MTC               | All of the five SSTR subtypes (predominantly SSTR2 and SSTR5)                            | [102, 103] |
| Neuroblastoma     | Mainly SSTR2                                                                             | [94]       |
| NSCLC             | Mainly SSTR2 and SSTR5 and, at lower level, SSTR3                                       | [104]      |
| Paraganglioma     | Predominantly SSTR2 and SSTR1                                                            | [94]       |
| PCa               | All of the five SSTR subtypes (predominantly SSTR1)                                      | [105, 106] |
| Phaeochromocytoma | Predominantly SSTR2 and SSTR1                                                            | [94]       |
| Pituitary adenoma | Typical pattern of SSTR expression according to the secreting cells from which they originate:         | [107–112] |
|                   | GH secreting: mostly SSTR2 and SSTR5, often together                                       |            |
|                   | ACTH secreting: predominantly SSTR2 together with SSTR5                                  |            |
|                   | PRL secreting: predominantly SSTR1 and SSTR5                                             |            |
|                   | TSH secreting: SSTR2 is mainly coexpressed with SSTR3 and SSTR5                          |            |
|                   | Clinically non-functioning: SSTR3 is highly expressed, followed by SSTR2 and, at lower level, SSTR5 |            |
| Renal cell carcinoma | Mainly SSTR2  |                                                                 | [94]       |
| Sarcoma           | Mainly SSTR2                                                                             | [94]       |
| SCLC              | Mainly SSTR2                                                                             | [94]       |

SSTR: somatostatin receptor; DTC: differentiated thyroid cancer; GBM: glioblastoma multiforme; GEP-NET: gastroenteropancreatic neuroendocrine tumor; GIST: gastrointestinal stromal tumor; HCC: hepatocellular carcinoma; MTC: medullary thyroid cancer; NSCLC: non-small cell lung cancer; PCa: prostate cancer; GH: growth hormone; ACTH: adrenocorticotropic hormone; PRL: prolactin; TSH: thyrotropin; SCLC: small cell lung cancer.

Figure 4: $^{68}$Ga-DOTATOC PET/CT images (MIP, sagittal) in a patient with metastatic small cell lung carcinoma.
| Reference          | Tumor type                                                                 | Method                             | Purpose                        | Results                                                                 |
|--------------------|----------------------------------------------------------------------------|-----------------------------------|--------------------------------|------------------------------------------------------------------------|
| Hofmann et al. 2001 [15] | Bronchial carcinoid ($n = 2$)                                               | $^{68}$Ga-DOTATOC PET             | Mts detection                  | Overall sensitivity = 100%*                                               |
| Koukouraki et al. 2006 [40] | Paraganglioma ($n = 1$); pulmonary carcinoid ($n = 2$); thymic carcinoid ($n = 1$); MTC ($n = 1$) | $^{68}$Ga-DOTATOC PET (dynamic)   | Evaluation of pharmacokinetics | Detection rate = 3/4 in paraganglioma = 5/5 in lung carcinoid = 3/3 in thymus carcinoid |
| Koukouraki et al. 2006 [67] | Paraganglioma ($n = 1$); pulmonary carcinoid ($n = 2$); thymic carcinoid ($n = 2$); MTC ($n = 1$); Merkel cell carcinoma ($n = 1$) | $^{68}$Ga-DOTATOC PET (dynamic)   | Evaluation of pharmacokinetics | Detection rate = 97%*                                                   |
| Gabriel et al. 2007 [41] | Paraganglioma ($n = 3$); bronchial carcinoid ($n = 6$); prostate NET ($n = 1$) | $^{68}$Ga-DOTATOC PET             | Staging/follow-up              | Overall sensitivity = 97%*                                               |
| Fanti et al. 2008 [31] | Paraganglioma ($n = 3$); prostate NET ($n = 3$); lymphoma ($n = 1$)          | $^{68}$Ga-DOTANOC PET/CT          | Restaging/treatment planning   | Positive in 4/7 cases                                                   |
| Ambrosini et al. 2010 [48] | Paraganglioma ($n = 5$); lung carcinoid ($n = 44$); Merkel cell carcinoma ($n = 1$); prostate NET ($n = 2$); melanoma ($n = 1$); thymic cancer ($n = 1$) | $^{68}$Ga-DOTANOC PET/CT          | Bone mts detection            | Overall sensitivity = 100%*                                               |
| Haug et al. 2010 [50] | Paraganglioma ($n = 1$); lung NET ($n = 4$)                                | $^{68}$Ga-DOTATATE PET/CT         | Outcome prediction             | $^{68}$Ga-DOTATATE uptake in tumor after the first cycle of PRRT predicted time to progression and correlated with an improvement in clinical symptoms |
| Naji et al. 2011 [33] | Paraganglioma ($n = 4$); phaeochromocytoma ($n = 7$); MTC ($n = 1$)         | $^{68}$Ga-DOTATATE PET or PET/CT | Staging/restaging              | Positive in 10/12 cases                                                 |
| Maurice et al. 2012 [37] | Paraganglioma ($n = 6$); phaeochromocytoma ($n = 9$)                        | $^{68}$Ga-DOTATATE PET/CT         | Diagnosis/follow-up            | Overall sensitivity = 80%*                                               |
| Mittal et al. 2013 [32] | Paraganglioma ($n = 3$); phaeochromocytoma ($n = 2$); neuroblastoma ($n = 8$); DTC ($n = 5$); thymic carcinoid ($n = 1$); mesenchymal tumor ($n = 8$) | $^{68}$Ga-DOTATATE PET/CT         | Staging/re-staging/treatment response assessment | Positive in 20/27 cases                                                  |
| Sharma et al. 2013 [38] | Paraganglioma ($n = 26$)                                                    | $^{68}$Ga-DOTANOC PET/CT          | Staging                        | All positive                                                           |
| Win et al. 2006 [34] | Phaeochromocytoma ($n = 5$)                                                 | $^{68}$Ga-DOTATATE PET            | Staging/re-staging             | Positive in 4/5 cases                                                   |
| Win et al. 2007 [35] | Phaeochromocytoma ($n = 5$)                                                 | $^{68}$Ga-DOTATATE PET            | Staging/re-staging             | Positive in 4/5 cases                                                   |
| Kroiss et al. 2011 [36] | Phaeochromocytoma ($n = 6$); neuroblastoma ($n = 5$)                        | $^{68}$Ga-DOTATOC PET/CT          | PRRT selection                 | Sensitivity = 92% for phaeochromocytoma = 97% for neuroblastoma         |
| Reference               | Tumor type                                                                                                                                                                                                 | Method                  | Purpose                            | Results                                                                 |
|------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------|------------------------------------|-------------------------------------------------------------------------|
| Hofman et al. 2012 [39]| Phaeochromocytoma (n = 4); mesenchymal tumor (n = 2)                                                                                                                                                       | 68Ga-DOTATATE PET/CT    | Staging                            | High/moderate management impact = 57%                                   |
| Miederer et al. 2009 [66]| Lung carcinoid (n = 1); MTC (n = 2); thymoma (n = 1)                                                                                                                                                       | 68Ga-DOTATOC PET/CT     | Detection                          | Correlation between immunohistochemistry-SSTR2 score and SUV*           |
| Ambrosini et al. 2009 [42]| Bronchial carcinoid (n = 11)                                                                                                                                                                                  | 68Ga-DOTANOC PET/CT     | Staging                            | Change in clinical management = 33%                                    |
| Kayani et al. 2009 [43]| Typical carcinoid (n = 11); atypical carcinoid (n = 2); large cell neuroendocrine tumor (n = 1); small cell neuroendocrine carcinoma (n = 1); NSCLC with neuroendocrine differentiation (n = 1); diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (n = 2) | 68Ga-DOTATATE PET/CT    | Staging/re-staging                 | Positive in 16/18 cases                                                 |
| Kumar et al. 2009 [44]| Bronchial carcinoid tumor (n = 3); inflammatory myofibroblastic tumor (n = 1); mucoepidermoid carcinoma (n = 1); hamartoma (n = 1); synovial cell sarcoma (n = 1)                                                  | 68Ga-DOTATATE PET/CT    | Bronchial mass detection           | Positive in 4/7 cases                                                   |
| Putzer et al. 2009 [49]| Lung NET (n = 5); prostate NET (n = 1)                                                                                                                                                                      | 68Ga-DOTATOC PET        | Mts detection                      | Overall sensitivity = 97%                                               |
| Jindal et al. 2010 [46]| Pulmonary carcinoid (n = 20)                                                                                                                                                                                | 68Ga-DOTATOC PET/CT     | Staging                            | Detection rate = 95%                                                   |
| Jindal et al. 2011 [45]| Pulmonary carcinoid (n = 20)                                                                                                                                                                                | 68Ga-DOTATOC PET/CT     | Staging                            | Detection rate = 100% for typical carcinoid = 86% for atypical carcinoid|
| Putzer et al. 2013 [47]| Lung NET (n = 4); SCLC (n = 7); bronchial carcinoid (n = 3); MTC (n = 8)                                                                                                                                 | 68Ga-DOTALAN versus 68Ga-DOTATOC PET | Detection/staging          | Overall sensitivity = 63% for 68Ga-DOTALAN PET* = 78% for 68Ga-DOTATOC PET* |
| Dimitrakopoulou-Strauss et al. 2006 [51]| NSCLC (n = 9)                                                                                                                                                                                               | 68Ga-DOTATOC PET (dynamic) | Staging/re-staging                 | Detection rate = 7/9 primary site = 0/8 mts                          |
| Sollini et al. 2013 [52]| SCLC (n = 24)                                                                                                                                                                                               | 68Ga-DOTATOC/DOTATATE PET/CT | PRRT selection                     | Positive in 20/24 cases                                                |
| Heute et al. 2010 [54]| Glioblastoma (n = 3)                                                                                                                                                                                        | 68Ga-DOTATOC PET        | PRRT selection                      | All positive                                                           |
| Waitz et al. 2011 [53]| Glioma (n = 33); medulloblastoma (n = 2); anaplastic astrocytoma (n = 1); glioblastoma (n = 13); meningioma (n = 22)                                                                                  | 68Ga-DOTATOC PET        | PRRT selection                      | Positive in 39/41 cases                                                |
| Gains et al. 2011 [55]| Neuroblastoma (n = 8)                                                                                                                                                                                         | 68Ga-DOTATATE PET/CT    | PRRT selection                      | Positive in 6/8 cases                                                   |
| Henze et al. 2001 [61]| Meningioma (n = 3)                                                                                                                                                                                             | 68Ga-DOTATOC PET (dynamic) | Evaluation of pharmacokinetics     | All positive                                                           |
| Reference                        | Tumor type          | Method                              | Purpose                                      | Results                                                                 |
|---------------------------------|---------------------|-------------------------------------|----------------------------------------------|------------------------------------------------------------------------|
| Henze et al. 2005 [62]          | Meningioma \((n = 21)\) | \(^{68}\)Ga-DOTATOC PET (dynamic)   | Evaluation of pharmacokinetics before EBRT   | Higher \(^{68}\)Ga-DOTATOC uptake in meningioma compared to reference tissue |
| Milker-Zabel et al. 2006 [57]   | Meningioma \((n = 26)\) | \(^{68}\)Ga-DOTATOC PET             | EBRT planning                                | Change in planning target volume = 73%                                  |
| Gehler et al. 2009 [58]         | Meningioma \((n = 26)\) | \(^{68}\)Ga-DOTATOC PET/CT          | EBRT planning                                | Change in clinical target volume = 54%                                  |
| Nyuyki et al. 2010 [59]         | Meningioma \((n = 42)\) | \(^{68}\)Ga-DOTATOC PET/CT          | EBRT planning                                | Change in gross tumor volume = 93%                                    |
| Afshar-Oromieh et al. 2012 [56] | Meningioma \((n = 134)\) | \(^{68}\)Ga-DOTATOC PET/CT          | Staging/re-staging                           | Detection rate = 100%                                                  |
| Graf et al. 2012 [60]           | Meningioma \((n = 16)\) | \(^{68}\)Ga-DOTATOC PET/CT          | EBRT planning                                | All positive                                                            |
| H"anscheid et al. 2012 [63]     | Meningioma \((n = 11)\) | \(^{68}\)Ga-DOTATOC/DOTATATE PET    | Prediction PRRT radionuclide retention       | Significant correlations between SUV\(_{max}\) and the therapeutic uptake, SUV\(_{max}\) and the maximum voxel dose from PRRT |
| Conry et al. 2010 [64]          | MTC \((n = 18)\)     | \(^{68}\)Ga-DOTATATE PET/CT         | Recurrence/mts detection                     | Positive in 13/18 cases                                                 |
| Treglia et al. 2012 [65]        | MTC \((n = 18)\)     | \(^{68}\)Ga-DOTATATE PET/CT         | Recurrence/mts detection                     | Positive in 6/18 cases                                                  |
| Middendorp et al. 2010 [68]     | DTC \((n = 17)\)     | \(^{68}\)Ga-DOTATOC PET/CT          | Recurrence/mts detection                     | Detection rate = 31% for radioiodine-negative lesions = 46% for radioiodine positive lesions |
| Gabriel et al. 2010 [69]        | DTC \((n = 6)\)      | \(^{68}\)Ga-DOTALAN/DOTATOC PET     | PRRT selection                               | NA                                                                      |
| Versari et al. 2013 [70]        | DTC \((n = 41)\)     | \(^{68}\)Ga-DOTATOC PET/CT          | PRRT selection                               | Positive in 24/41 cases                                                |
| Haug et al. 2012 [80]           | DTC \((n = 3)\); colorectal cancer \((n = 1)\); lymphoma \((n = 1)\) | \(^{68}\)Ga-DOTATATE PET/CT         | Recurrence detection                         | Overall sensitivity = 90%\(^\ast\)                                    |
| Schneider et al. 2012 [74]      | Merkel cell carcinoma \((n = 1)\) | \(^{68}\)Ga-DOTATOC PET/CT          | Staging                                      | Positive                                                                |
| Schmidt et al. 2012 [75]        | Merkel cell carcinoma \((n = 2)\) | \(^{68}\)Ga-DOTATOC PET/CT          | PRRT selection                               | Both positive                                                           |
| Salavati et al. 2012 [76]       | Merkel cell carcinoma \((n = 1)\) | \(^{68}\)Ga-DOTATOC PET/CT          | PRRT selection                               | Positive                                                                |
| Epstude et al. 2013 [77]        | Merkel cell carcinoma \((n = 1)\) | \(^{68}\)Ga-DOTATOC PET/CT          | PRRT selection                               | Positive                                                                |
| Desai et al. 2011 [81]          | Colorectal cancer \((n = 1)\) | \(^{68}\)Ga-DOTATATE PET            | Detection                                    | Positive                                                                |
| Elgeti et al. 2008 [78]         | Breast cancer \((n = 2)\) | \(^{68}\)Ga-DOTATOC PET/CT          | Detection                                    | Both positive                                                           |
| Souvatzoglou et al. 2009 [83]   | Prostate cancer \((n = 1)\) | \(^{68}\)Ga-DOTATOC PET/CT          | Staging                                      | Positive                                                                |
| Luboldt et al. 2010 [84]        | Prostate cancer \((n = 20)\) | \(^{68}\)Ga-DOTATOC PET/CT          | Bone mts detection                           | Detection rate = 30%                                                   |
| Alonso et al. 2011 [85]         | Prostate cancer \((n = 1)\) | \(^{68}\)Ga-DOTATATE PET/CT         | Mts detection                               | Positive                                                                |
Table 2: Continued.

| Reference                  | Tumor type                        | Method                  | Purpose                  | Results                     |
|----------------------------|-----------------------------------|-------------------------|--------------------------|-----------------------------|
| Broggsitter et al. 2013    | Melanoma (n = 18)                 | 68Ga-DOTATOC PET/CT     | Staging/re-staging       | Positive in 11/18 cases     |
| Vasamilett et al. 2009     | Thymoma (n = 1)                   | 68Ga-DOTATOC PET        | PRRT selection           | Positive only in primary tumor |
| Dutta et al. 2010          | Thymic carcinoma (n = 3)          | 68Ga-DOTATOC PET/CT     | Staging                  | All negative                |
| Froio et al. 2013          | Thymic malignancy (n = 39)        | 68Ga-DOTATOC/DOTATATE PET/CT | Staging/re-staging | Detection rate = 20% |
| von Fackl et al. 2008      | Mesenchimal tumor (n = 1)         | 68Ga-DOTATOC PET/CT     | Detection                | Positive                    |
| Woff et al. 2010           | Mesenchimal tumor (n = 1)         | 68Ga-DOTATOC PET        | Detection                | Positive                    |
| Clifton-Bligh et al. 2013  | Mesenchimal tumor (n = 6)         | 68Ga-DOTATOC PET/CT     | Detection                | All positive                |

PET: positron emission tomography; PET/CT: positron emission tomography/computed tomography; Mts: metastases; MTC: medullary thyroid cancer; NET: neuroendocrine tumor; PRRT: peptide radioreceptor therapy; DTC: differentiated thyroid cancer; NA: not available; NSCLC: non-small cell lung cancer; SCLC: small cell lung cancer; EBRT: external beam radiotherapy.

Overall results (no specific results for each tumor type).

68Ga-DOTANOC PET/CT provided additional information in 82% of patients changing the clinical management in 33% of cases. Kayani et al. [43] compared the performance of 68Ga-DOTATATE PET/CT to [18F]FDG-PET/CT in the detection of pulmonary NET and correlated the PET radiotracer uptake to tumor grade on histology (II typical carcinoids, 2 atypical carcinoids, 1 large cell neuroendocrine tumor, 1 small cell neuroendocrine carcinoma, 1 non-small cell lung cancer with neuroendocrine differentiation, and 2 cases of diffuse idiopathic pulmonary neuroendocrine cell hyperplasia). All typical carcinoids showed high 68Ga-DOTATATE uptake (SUV_{max} ≥ 8.2), but 4/11 showed negative or faint [18F]FDG uptake (SUV_{max} = 1.7–2.9), while atypical carcinoids showed high uptake of [18F]FDG (SUV_{max} ≥ 11.7), but 3/5 showed only faint accumulation of 68Ga-DOTATATE (SUV_{max} = 2.2–2.8). Neither case of diffuse idiopathic pulmonary neuroendocrine cell hyperplasia showed 68Ga-DOTATATE or [18F]FDG uptake. No false-positive results were observed on 68Ga-DOTATATE PET/CT, while [18F]FDG-PET/CT was false-positive in 3 cases due to inflammation. Kumar et al. [44] compared 68Ga-DOTATATE and [18F]FDG PET/CT in 7 patients with bronchial mass detected by CT (carcinoid tumors, n = 3; inflammatory myofibroblastic tumor, n = 1; mucoidpidermoid carcinoma, n = 1; hamartoma, n = 1; synovial cell sarcoma, n = 1). The typical carcinoids had mild [18F]FDG uptake and high 68Ga-DOTATOC uptake. Atypical carcinoid had moderate [18F]FDG uptake and high 68Ga-DOTATOC uptake. Inflammary myofibroblastic tumor and mucopidermoid carcinoma were positive on [18F]FDG-PET/CT (high and moderate uptake, resp.) and both were negative using 68Ga-DOTATOC PET/CT. Hamartoma showed no uptake on either [18F]FDG or 68Ga-DOTATOC PET/CT scans. Synovial cell sarcoma showed moderate [18F]FDG uptake and mild focal 68Ga-DOTATOC uptake. More recently, Jindal et al. [45] reported similar results in 20 patients with pulmonary carcinoids (13 typical and 7 atypical). In this series all the atypical carcinoids revealed higher uptake on the [18F]FDG-PET/CT than that in typical carcinoids while SUV_{max} was significantly higher in typical carcinoids (SUV_{max} = 8.8–66) compared with atypical carcinoids (SUV_{max} = 1.1–18.5) on 68Ga-DOTATOC PET/CT. Jindal et al. [46] in a retrospective analysis of patients with primary pulmonary carcinoid (n = 20) who underwent 68Ga-DOTATOC PET/CT reported a detection rate of 95%. Putzer et al. [47] compared 68Ga-DOTALAN to 68Ga-DOTATOC PET in 53 patients with cancer including NET of the lung (n = 4), SCLC (n = 7), and bronchial carcinoid (n = 3). Results showed that 68Ga-DOTATOC has a clear advantage over 68Ga-DOTALAN in detection and staging of this series of NETs.

68Ga-SST-analogues PET/CT has also been compared to CT and bone scintigraphy for the evaluation of bone metastases in patients with lung NET being more accurate than CT and bone scintigraphy for the early identification of bone lesions [48, 49]. Finally, 68Ga-DOTATATE PET/CT has also been evaluated to predict progression-free survival and clinical outcome after peptide radioreceptor therapy (PRRT) in a series of patients with well-differentiated NET including 4 cases with lung NET. Results showed that patients with a decline in tumor-to-spleen SUV ratio (SUV_{TS}) after finishing the first cycle of PRRT had a significant longer time to progression than patients without favorable SUV_{TS} changes, suggesting that this parameter has a potential role in the early prediction of outcome in patients with well-differentiated NET [50].

Dimitrakopoulou-Strauss et al. [51] compared SSTR expression assessed by 68Ga-DOTATOC PET to tumor viability assessed by [18F]FDG-PET in 9 patients with NSCLC. Moderately enhanced 68Ga-DOTATOC uptake was noted in 7/9 primary tumors (mean SUV_{max} = 2.018
Table 3: Summary of the role of positron emission tomography and positron emission tomography/computed tomography with $^{68}$Ga-radiolabeled somatostatin analogues in tumors other than gastroenteropancreatic neuroendocrine tumors.

| Tumor type                  | References                  | Publications ($n =$) | Patients ($n =$) | $^{68}$Ga-somatostatin-analogues PET or PET/CT purpose | Future perspective* |
|-----------------------------|-----------------------------|----------------------|------------------|-----------------------------------------------------|---------------------|
| Sympathoadrenal system tumors |                             |                      |                  | Diagnosis/staging                                    |                     |
| Paraganglioma               | [31–33, 37, 38, 40, 41, 48, 50, 67] | 10                   | $\sum 53$       | x                                                     | x                   |
| Pheochromocytoma            | [32–37, 39]                 | 7                    | $\sum 38$       | x                                                     | x                   |
| Lung tumors                 |                             |                      |                  | PRRT selection                                       |                     |
| Carcinoid                   | [40–50, 66, 67]             | 13                   | $\sum 140$      | x                                                     | x                   |
| NSCLC                       | [43, 51]                    | 2                    | $\sum 10$       | x                                                     | x                   |
| SCLC                        | [43, 47, 52]                | 3                    | $\sum 32$       | x                                                     | x                   |
| Brain tumors                |                             |                      |                  | Other                                                |                     |
| Neuroepithelial tumor       | [32, 36, 53–55]             | 5                    | $\sum 45$       | x                                                     | x                   |
| Meningioma                  | [53, 55–63]                 | 9                    | $\sum 301$      | x                                                     | x                   |
| Thyroid cancers             |                             |                      |                  | Other                                                |                     |
| MTC                         | [33, 40, 47, 64–67]         | 7                    | $\sum 48$       | x                                                     | x                   |
| DTC                         | [32, 68–70, 80]             | 5                    | $\sum 72$       | x                                                     | x                   |
| Merkel cell carcinoma       | [48, 67, 74–77]             | 6                    | $\sum 7$        | x                                                     | x                   |
| Colorectal cancer           | [80, 81]                    | 2                    | $\sum 2$        | x                                                     | x                   |
| Breast cancer               | [78]                        | 1                    | $\sum 2$        | x                                                     | x                   |
| Prostate cancer             | [31, 41, 48, 49, 83–85]     | 7                    | $\sum 29$       | x                                                     | x                   |
| Melanoma                    | [48, 82]                    | 2                    | $\sum 19$       | x                                                     | x                   |
| Thymic cancer               | [40, 48, 66, 67, 71–73]     | 8                    | $\sum 51$       | x                                                     | x                   |
| Mesenchymal tumor           | [32, 39, 86–88]             | 5                    | $\sum 18$       | x                                                     | x                   |
| Lymphoma                    | [31, 80]                    | 2                    | $\sum 2$        | x                                                     | x                   |

PET: positron emission tomography; PET/CT: positron emission tomography/computed tomography; PRRT: peptide radioreceptor therapy; NSCLC: non-small cell lung cancer; SCLC: small cell lung cancer; MTC: medullary thyroid cancer; DTC: differentiated thyroid cancer. *Based on literature data we classified the use of radiolabeled somatostatin analogues PET or PET/CT as ++: suitable; +: promising; +/-: undetermined; and −: not indicated.
for $^{68}$Ga-DOTATOC and 5.683 for $^{[18]}$F-FDG) but none of the 8 metastases which were positive on $^{[18]}$F-FDG-PET showed any $^{68}$Ga-DOTATOC uptake. These findings suggest a loss of the SSTR expression in metastases as compared with the NSCLC primary tumors.

Recently, we evaluated the performances of PET/CT with $^{68}$Ga-labeled SST-analogues in 24 patients with progressive extensive SCLC, to select patients for subsequent PRRT and compared $^{68}$Ga-labeled SST-analogues PET/CT results to contrast-enhanced CT findings. PET/CT was positive in 83% of patients and concordant to CT findings for all the sites of disease in 37.5% of cases [52].

In conclusion, the degree of uptake and different uptake patterns on $^{[18]}$F-FDG and $^{68}$Ga-SST-analogues PET or PET/CT may be helpful in differentiating between typical and atypical carcinoids. $^{68}$Ga-SST-analogues PET/CT may be useful also to stage disease in lung cancer and to select patients for the best treatment option, including PRRT.

4. Brain Neuroepithelial Tissue Tumors

The overexpression of SSTR has been reported in most high grade gliomas and it may be an interesting target for PRRT. $^{68}$Ga-DOTATOC PET showed SSTR expression (unpublished data from Innsbruck Medical University) in the majority of patients with brain tumors (89%) including glioma ($n = 3$), medulloblastoma ($n = 2$), anaplastic astrocytoma ($n = 1$), and glioblastoma ($n = 13$) with a different degree of radiotracer uptake (faint = 37%, medium = 21%, and intense = 31%) [53]. Mittal et al. [32] retrospectively evaluated 145 patients including neuroblastoma ($n = 8$) with $^{68}$Ga-DOTATATE PET/CT with different purposes (initial staging, $n = 6$; disease recurrence detection and response evaluation, $n = 1$ each). In all the patients evaluated PET/CT was positive and in 5/6 cases in which $^{68}$Ga-DOTATATE PET/CT was performed as initial stage it was able to detect metastatic site of disease. Kroiss et al. [36] compared $^{68}$Ga-DOTATOC PET/CT to $^{123}$I-MIBG scan in a series of patients including neuroblastoma ($n = 5$) reporting the superiority of PET/CT compared to scintigraphy (sensitivity of 97% and 91%, resp.). $^{68}$Ga-radiolabeled SST-analogues PET/CT has been also used to select patients for PRT (neuroblastoma, $n = 8$; glioma, $n = 3$) [54, 55] and to evaluate treatment response combined with other imaging modalities [54].

5. Meningioma

Several authors have investigated the role of $^{68}$Ga-labeled SST-analogues PET/CT in patients with intracranial meningioma. Virtually, all patients with meningioma present $^{68}$Ga-labeled SST-analogues uptake (Figure 5). Afshar-Oromieh et al. [56] compared diagnostic accuracy of $^{68}$Ga-DOTATOC PET/CT to brain contrast-enhanced MRI in a large series of meningioma patients before radiotherapy. In the 134 patients investigated by both modalities, 190 meningiomas were detected by $^{68}$Ga-DOTATOC PET/CT and 171 by contrast-enhanced MRI. With the knowledge of the PET/CT data, MRI scans were reinvestigated, leading to the detection of 4 of the 19 incidental meningiomas, resulting in an overall detection rate of 92% of the meningioma lesions that have been found by PET/CT. Milker-Zabel et al. [57] compared the planning target volume outlined on CT and contrast-enhanced MRI to the planning target volume outlined on $^{68}$Ga-DOTATOC PET. Patients were treated according to the planning target volume defined with CT, MRI, and PET. The planning target volume defined with CT, MRI, and PET was somewhat larger than the volume detectable in MRI/CT (median 57.2 cc and 49.6 cc, resp.). In all patients $^{68}$Ga-DOTATOC PET delivered additional information concerning tumor extension and the planning target volume was significantly modified based on $^{68}$Ga-DOTATOC PET data in 73% of the cases. Similarly, Gehler et al. [58] defined the gross tumor volume by MRI, CT, and $^{68}$Ga-DOTATOC PET/CT in 26 patients with meningioma. Initial gross tumor volume definition was only based on radiological data and was secondarily integrated with $^{68}$Ga-DOTATOC PET/CT information. $^{68}$Ga-DOTATOC PET/CT provided additional information concerning tumor extension in 65% of patients (especially for skull base manifestations and recurrent disease after surgery) and modified the planning target volume in more than half of patients. Nyuykiet al. [59] investigated the potential value of $^{68}$Ga-DOTATOC PET/CT in the definition of the gross tumor volume in 42 meningioma patients before radiotherapy. $^{68}$Ga-DOTATOC PET/CT findings were compared to CT and MRI. Results showed that $^{68}$Ga-DOTATOC PET/CT enabled delineation of SSTR-positive meningiomas and provided additional information compared to both CT and MRI regarding the planning of stereotactic radiotherapy (particularly for the detection of osseous infiltration). Additionally, in a subgroup of patients with multiple meningiomas, $^{68}$Ga-DOTATOC PET/CT was able to identify more lesions compared to CT or MRI (19 versus 10, resp.). Similarly, Graf et al. [60] retrospectively compared $^{68}$Ga-DOTATOC PET/CT to MRI and CT in the delineation of infracranial extension of skull base meningiomas in 16 patients subsequently treated with fractionated stereotactic radiotherapy. The mean infracranial volume delineable in PET was somewhat larger than the volume detectable in MRI/CT (10.1 ± 10.6 cm$^3$ and 8.4 ± 7.9 cm$^3$, resp.). However, authors have concluded that $^{68}$Ga-DOTATOC PET/CT may be useful for planning fractionated stereotactic radiation when used in addition to conventional imaging modalities often inconclusive in the skull base region. Henze et al. [61, 62] characterized meningioma with dynamic $^{68}$Ga-DOTATOC PET in order to evaluate kinetic parameters reporting a good correlation with MRI and CT findings and a significant difference of radiotracer uptake between meningioma and reference tissue (mean SUV = 10.5 and 1.3, resp.) suggesting a possible role of $^{68}$Ga-DOTATOC PET/CT in monitoring meningioma SSTR expression after radiotherapy. Recently, Hänisch et al. [63] evaluated the predictive role of $^{68}$Ga-labeled SST-analogues PET to assess tumor radionuclide uptake in PRRT of meningioma. Results showed a strong correlation between SUV$_{max}$ and PRRT radionuclide tumor retention in the voxels with the highest uptake suggesting a potential role of $^{68}$Ga-labeled
SST-analogues PET to estimate the PRRT achievable dose. Therefore $^{68}$Ga-labeled SST-analogues PET/CT may provide additional information in patients with uncertain or equivocal results using MRI or could help to confirm a diagnosis of meningioma based on MRI or may help to confirm MRI-based diagnosis of meningioma in cases of biopsy limitations. Finally, $^{68}$Ga-labeled SST-analogues PET or PET/CT may be useful to delineate the target volume for fractionated stereotactic radiotherapy.

6. Medullary Thyroid Cancer

Although studies investigating larger and more homogeneous patient populations are needed to better elucidate the potential diagnostic role of new PET tracers for the assessment of recurrent medullary thyroid carcinoma (MTC), the preliminary published data seem to suggest that the diagnostic role of $^{68}$Ga-SST-analogues appears to be controversial (Figure 6). In fact, well-differentiated tumors show a variable and often low SSTR subtype cell expression. Of course, the evidence of a high uptake of $^{68}$Ga-labeled SST-analogues could be used to accurately define the tumor biology “map” and therefore may be potentially helpful in selecting the most appropriate therapeutic option. Conry et al. [64] compared the sensitivity of $^{68}$Ga-DOTATATE PET/CT to $[^{18}\text{F}]$FDG-PET/CT in a series of 18 patients with recurrent MTC. Although the overall detection rate for both procedures was comparable (positive results in 72% and 77% of the cases for $^{68}$Ga-DOTATATE and $[^{18}\text{F}]$FDG, resp.), on a region-based analysis $[^{18}\text{F}]$FDG-PET identified more metastatic lesions than $^{68}$Ga-DOTATATE PET/CT (28 versus 23, resp.). Treglia et al. [65] retrospectively compared PET/CT with $^{68}$Ga-DOTATATE, $[^{18}\text{F}]$FDG, and $[^{18}\text{F}]$DOPA in 18 patients with residual/recurrent MTC suspected on the basis of elevated serum calcitonin levels. Results showed statistically different sensitivity values between $[^{18}\text{F}]$DOPA and $[^{18}\text{F}]$FDG-PET/CT (72% and 17%, resp.) and between $[^{18}\text{F}]$DOPA and $^{68}$Ga-DOTATATE PET/CT (72% and 33%, resp.). Miederer et al. [66] compared a score of SSTR2 immunoistochemistry with the in vivo SUV of preoperative or prebiopsy $^{68}$Ga-DOTATOC PET/CT in a small series of patients including 2 patients with metastases from MTC. In these patients who were negative on immunohistochemistry PET/CT showed a moderate $^{68}$Ga-DOTATOC uptake (SUV$_{\text{max}} = 4.4$ and 6.8). Koukouraki et al. [67] evaluating the pharmacokinetics of $^{68}$Ga-DOTATOC in series of patients with metastatic NET reported the lowest $^{68}$Ga-DOTATOC uptake in the patient with MTC. In another series of patients, including one case of MTC, Koukouraki et al. [40] compared $^{68}$Ga-DOTATOC
Figure 6: $^{68}$Ga-DOTATATE PET/CT images (MIP, axial) in a patient affected by metastatic medullary thyroid carcinoma.

Very recently, Putzer et al. [47] compared $^{68}$Ga-DOTALAN to $^{68}$Ga-DOTATOC PET in 53 patients with cancer including 8 patients with MTC. In this series of NETs, $^{68}$Ga-DOTATOC PET showed a clear advantage over $^{68}$Ga-DOTALAN PET in both lesion detection and staging.

7. Differentiated Thyroid Carcinoma

Although papillary, follicular, and anaplastic thyroid cancers and also Hurthle-cell carcinomas do not belong to the group of traditional NET, $^{68}$Ga-SST-analogues PET and PET/CT may be positive in many patients (Figure 7) and could provide, especially in negative radioiodine cases, new therapeutic options. Mittal et al. [32] retrospectively evaluated 145 patients including differentiated thyroid carcinoma (DTC) patients presenting thyroglobulin-elevated negative iodine scan ($n = 5$) with $^{68}$Ga-DOTATATE PET/CT. In all patients evaluated, PET/CT was positive (cervical nodes, $n = 3$; remnant and cervical nodes, $n = 1$; thyroid bed soft tissue nodule, $n = 1$). Middendorp et al. [68] compared $^{68}$Ga-DOTATOC PET/CT to $[^{18}\text{F}]$FDG-PET/CT in 17 patients with recurrent DTC. Both PET tracers consistently detected metastases in 12 patients. $[^{18}\text{F}]$FDG-PET/CT has been reported more sensitive compared to $^{68}$Ga-DOTATOC PET/CT in the detection of radioiodine negative lesions (64% versus 31%) but not in radioiodine positive lesions (48% versus 46%). On a lesion-by-lesion basis, only 2% of lesions were visible using $^{68}$Ga-DOTATOC PET/CT. Gabriel et al. [69] reported the usefulness of $^{68}$Ga-SST analogues PET/CT to identify patients with thyroid cancer with radioiodine negative metastases ($n = 6$) suitable for PRRT. Similarly, our group used $^{68}$Ga-DOTATOC PET/CT to select patients with radioiodine negative metastatic DTC ($n = 41$) for PRRT [70].

8. Thymic Malignancies

Few data are available about the role of $^{68}$Ga-SST-analogues PET in thymic malignancies [40, 48, 66, 67, 71–73]. Miederer et al. [66] compared a score of SSTR2 immunohistochemistry with the in vivo SUV of preoperative or pre-biopsy $^{68}$Ga-DOTATOC PET/CT in a small series of patients including one case of thymoma. In this patient who was negative on immunohistochemistry, PET/CT showed a faint $^{68}$Ga-DOTATOC uptake ($\text{SUV}_{\text{max}} = 2.5$). Dutta et al. [72] investigated 3 patients with thymic carcinoid tumors by $^{68}$Ga-DOTATOC PET/CT but none of these tumors showed radiotracer uptake. Koukouraki et al. [40] compared $^{68}$Ga-DOTATOC PET to $[^{18}\text{F}]$FDG-PET in a series of patients including one case of carcinoid of thymus in which the disease was correctly addressed by both PET radiotracers. We reported a series of 39 patients with metastatic thymic malignancies evaluated by $^{68}$Ga-SST-analogues PET/CT and $[^{18}\text{F}]$FDG-PET/CT. $^{68}$Ga-SST-analogues PET/CT and $[^{18}\text{F}]$FDG-PET/CT were concordant in 43% of cases (both positive in 36% of cases and both negative in 8% of patients); in 52% of patients $[^{18}\text{F}]$FDG-PET/CT was positive and $^{68}$Ga-SST-analogues PET/CT was negative while in the remaining 5% of cases $^{68}$Ga-SST-analogues PET/CT was positive and $[^{18}\text{F}]$FDG-PET/CT was negative. In a per-lesion analysis, all lesions shown by contrast enhanced CT scan, which was considered the gold standard, were detected in 20% and 43% of cases using $^{68}$Ga-SST-analogues and $[^{18}\text{F}]$FDG, respectively; in the remaining cases we observed at least one measurable CT lesion without either $^{68}$Ga-SST-analogues or $[^{18}\text{F}]$FDG uptake. In this series of thymic neoplasms at restaging a predominant $[^{18}\text{F}]$FDG positivity was observed compared to $^{68}$Ga-SST-analogues at PET/CT suggesting a relative loss of SSTR expression during thymic malignancies progression and a subsequent increasing of biological aggressiveness [73] (Figure 8).

9. Merkel Cell Carcinoma

Merkel cell tumors are aggressive neoplasms that often metastasize and, despite therapy, the disease-related death rate is high. Ultrastructurally and immunocytochemically,
Figure 7: $^{68}$Ga-DOTATATE PET/CT images (MIP, axial) in a patient with metastatic iodine-negative differentiated thyroid carcinoma.

Figure 8: $^{68}$Ga-DOTATATE PET/CT images (MIP, axial) in a patient with thymoma.

10. Breast Cancer

In breast cancer differentiated tumors express more SSTR2 than undifferentiated ones, and estrogens positively affect SSTR2 expression; additionally, the research of new factors that could allow a more accurate prognosis of the existing disease and that could improve traditional treatment strategies remains critical [29]. However no sufficient data are available about the role of $^{68}$Ga-SST-analogues PET or PET/CT in this clinical setting (Figure 9). Elgeti et al. [78] retrospectively analyzed $^{68}$Ga-DOTATOC PET/CT performed for staging purpose in 33 women with NET. In 6/33 patients $^{68}$Ga-DOTATOC PET/CT revealed the presence of a breast lesion classified as suspected in 4/6 cases. In 2 cases the suspected breast lesion was diagnosed as NET metastases while in the remaining 2 cases it was diagnosed as primary breast cancer resulting in a change of therapeutic management. Primary breast cancer presented a lower $^{68}$Ga-DOTATOC uptake compared to concomitant abdominal NET lesions. In this small series of patients $^{68}$Ga-DOTATOC PET/CT not only improved NET staging but also increased the chance to detect...
SSTR-positive breast cancer. In the case of breast lesions, authors suggested further diagnostic characterization since the confirmation of a secondary tumor impact on therapeutic management of patients.

11. Colorectal Cancer

Some data suggest that SSTR2 gene expression in colorectal cancer might be related to a more favorable outcome [79]. However, no sufficient data are available about the role of $^{68}$Ga-SST-analogues PET/CT in this clinical setting [80, 81]. Desai et al. [81] reported the usefulness of molecular imaging using different PET radiotracers in order to understand NET biology and subsequently to determine the best treatment option. In this case a different tumor pattern of $^{18}$F]FDG and $^{68}$Ga-DOTATATE uptake was shown by PET examinations within the liver, resulting in synchronous colorectal cancer and pancreatic NET liver metastases.

12. Melanoma

Few cases have been reported in the literature about the role of $^{68}$Ga-labeled SST-analogues PET/CT in melanoma patients [48, 82]. Brogsitter et al. [82] compared $^{68}$Ga-DOTATOC PET/CT to $^{18}$F]FDG-PET/CT in 18 patients with metastatic melanoma. $^{68}$Ga-DOTATOC PET/CT was positive in 61% of the investigated patients; however, on a lesion-by-lesion basis, only 22% of $^{18}$F]FDG-positive metastases were seen with $^{68}$Ga-DOTATOC PET/CT. Further, $^{68}$Ga-DOTATOC uptake was only faint (mean SUV$_{max}$ = 3.1, range 1.2–4.2) compared to $^{18}$F]FDG (mean SUV$_{max}$ = 28.2, range 2.3–115). The exact impact of $^{68}$Ga-SST-analogues PET/CT on staging and management of melanoma patient remains to be determined.

13. Prostate Cancer

Few cases have been reported in the literature about the role of $^{68}$Ga-labeled SST-analogues PET/CT in prostate cancer patients [31, 41, 48, 49, 83–85]. Luboldt et al. [84] assessed SSTR expression in 20 patients with advanced prostate cancer to potentially guide SSTR-mediated therapies. On a side-by-side analysis only 30% of bone scintigraphy-positive metastases were seen with $^{68}$Ga-DOTATOC PET/CT. The authors concluded by suggesting further studies with different SST-analogues with a higher affinity for SSTR1 and SSTR4 (expressed by prostate cancer), not adequately addressed with DOTATOC. The only case reported in the literature using $^{68}$Ga-DOTATATE showed intense radiotracer uptake in bone metastases, confirming bone scan results and suggesting a potential role of $^{68}$Ga-DOTATATE PET/CT to guide SSTR-mediated therapies also in this clinical setting [85].

14. Mesenchymal Tumors

Despite the promising results only few cases have been reported in the literature about the use of $^{68}$Ga-labeled SST-analogues PET/CT to evaluate tumor-induced osteomalacia (phosphaturic mesenchymal tumors) [32, 39, 86–88]. In the two larger series of patients ($n = 6$ and $n = 8$, resp.) with suspicious tumor-induced osteomalacia, PET/CT demonstrated high $^{68}$Ga-DOTATATE uptake and localized the tumor in 75–100% of the cases evaluated [32, 88].

In this clinical setting $^{68}$Ga-DOTATATE PET/CT may represent the first step functional imaging to identify the site of disease but further studies are needed to confirm these preliminary results.

15. Lymphoma

The use of $^{68}$Ga-labeled SST-analogues PET/CT in lymphoma is limited to sporadic cases [31, 80] (Figure 10).
16. Conclusion and General Remarks

The use of $^{68}$Ga-labeled SST-analogues PET/CT in pheochromocytoma and paraganglioma remains small, consisting mainly of case reports and small series. The diagnostic accuracy of $^{68}$Ga-SST-analogues PET/CT is superior to $^{131}$I-MIBG; thus, in the case of negative $^{123}$I-MIBG scan in patients with a high pretest probability of pheochromocytoma or paraganglioma, $^{68}$Ga-labeled SST-analogues PET/CT should be considered. Additionally, $^{68}$Ga-labeled SST-analogues PET/CT should be considered in the staging of patients in whom metastatic spread, particularly to the bone, is suspected.

Although limited experience exists in NCSCL and SCLC, $^{68}$Ga-SST-analogues PET or PET/CT has been evaluated in all types of lung tumor. Particularly, the degree of uptake and the different uptake patterns on $^{18}$F-FDG and $^{68}$Ga-SST-analogues PET or PET/CT may be helpful to differentiate typical from atypical carcinoids. $^{68}$Ga-SST-analogues PET/CT may be useful also to stage lung cancer (especially for the early identification of bone lesions) and to select patients for the best treatment option, including PRRT.

Some interesting studies on radiolabeled SST-analogues PET/CT in patients with brain neuroepithelial tumors (either for staging, treatment selection, or response evaluation) are reported in the literature.

$^{68}$Ga-labeled SST-analogues PET/CT has been widely used in patients with intracranial meningioma. $^{68}$Ga-labeled SST-analogues PET/CT provides additional information in patients with uncertain or equivocal results at MRI and helps to confirm a diagnosis of meningioma based on MRI or to confirm MRI-based diagnosis of meningioma in cases of biopsy limitations. Finally, $^{68}$Ga-labeled SST-analogues PET or PET/CT may be useful to delineate the target volume for fractionated stereotactic radiotherapy.

Although studies investigating larger and more homogeneous patient populations are needed to better elucidate the potential diagnostic role of radiolabeled SST-analogues for the assessment of recurrent MTC, the preliminary published data suggest a controversial role of $^{68}$Ga-SST-analogues since well-differentiated tumors show a variable and often low SSTR subtype cell expression. $^{68}$Ga-SST-analogues PET and PET/CT were positive in many patients with DTC providing, especially in negative radioiodine cases, new therapeutic options as PRRT. However, further studies comparing $^{68}$Ga-SST-analogues to radioiodine scintigraphy and $^{18}$F-FDG-PET/CT in DTC are needed.

Limited disappointing experience exists regarding the role of $^{68}$Ga-SST-analogues PET/CT in patients with thymic malignancies. In thymic neoplasms a predominant $^{18}$F-FDG positivity has been observed compared to $^{68}$Ga-SST-analogues at PET/CT suggesting a relative loss of SSTR expression during thymic malignancy progression and subsequent increasing of biological aggressiveness.

Few but significant data are available about the role of $^{68}$Ga-labeled SST-analogues PET/CT in Merkel cell carcinoma. $^{68}$Ga-labeled SST-analogues PET/CT is useful to stage and restage patients, and also to select treatment for PRRT and to assess treatment response.

Although only few cases have been reported in the literature about the use of $^{68}$Ga-labeled SST-analogues PET/CT in tumor-induced osteomalacia, $^{68}$Ga-DOTATATE PET/CT may represent the first step functional imaging to identify mesenchymal tumors; however further studies are needed to confirm the promising preliminary results.

No sufficient data are available about the role of $^{68}$Ga-SST-analogues PET or PET/CT in melanoma and breast, colorectal, and prostate cancers. The use of $^{68}$Ga-labeled SST-analogues PET/CT in lymphoma is limited to sporadic cases with unfavorable results.

In conclusion, although these preliminary experiences suggest a possible role of $^{68}$Ga-SST-analogues PET or PET/CT in many non GEP-NETs tumors, further studies are needed to confirm these promising results.

Conflict of Interests

All the authors declare that they have no conflict of interests.
References

[1] J. C. Reubi, “Peptide receptors as molecular targets for cancer diagnosis and therapy,” Endocrine Reviews, vol. 24, no. 4, pp. 389–427, 2003.

[2] J. C. Reubi and B. Waser, “Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 30, no. 5, pp. 781–793, 2003.

[3] E. Bombardieri, M. Maccario, E. De Deckere, G. Savelli, and A. Chiti, “Nuclear medicine imaging of neuroendocrine tumours,” Annals of Oncology, vol. 12, no. 2, pp. S51–S61, 2001.

[4] J. O. Olsen, R. V. Pozderac, G. Hinkde et al., “Somatostatin receptor imaging of neuroendocrine tumors with indium-111-pentetreotide (OctreoScan),” Seminars in Nuclear Medicine, vol. 25, no. 3, pp. 251–261, 1995.

[5] V. Briganti, R. Sestini, C. Orlando et al., “Imaging of somatostatin receptors by indium-111-pentetreotide correlates with quantitative determination of somatostatin receptor type 2 gene expression in neuroblastoma tumors,” Clinical Cancer Research, vol. 3, no. 12, pp. 2385–2391, 1997.

[6] A. Chiti, V. Briganti, S. Fanti, N. Monetti, R. Masi, and E. Bombardieri, “Results and potential of somatostatin receptor imaging in gastroenteropancreatic tract tumors,” Quarterly Journal of Nuclear Medicine, vol. 44, no. 1, pp. 42–49, 2000.

[7] A. Chiti, S. Fanti, G. Savelli et al., “Comparison of somatostatin receptor imaging, computed tomography and ultrasound in the clinical management of neuroendocrine gastro-enteropancreatic tumours,” European Journal of Nuclear Medicine, vol. 25, no. 10, pp. 1396–1403, 1998.

[8] E. P. Krenning, D. J. Kwékkeboom, W. H. Bakker et al., “Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients,” European Journal of Nuclear Medicine, vol. 20, no. 8, pp. 716–731, 1993.

[9] E. Seregni, A. Chiti, and E. Bombardieri, “Radio nuclide imaging of neuroendocrine tumours: biological basis and diagnostic results,” European Journal of Nuclear Medicine, vol. 25, no. 6, pp. 639–658, 1998.

[10] E. Jamar, R. Fiasse, N. Leners, and S. Pauwels, “Somatostatin receptor imaging with indium-111-pentetreotide in gastroenteropancreatic neuroendocrine tumours: safety, efficacy and impact on patient management,” Journal of Nuclear Medicine, vol. 36, no. 4, pp. 542–549, 1995.

[11] R. Lebthé, G. Cadiot, L. Sarda et al., “Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors,” Journal of Nuclear Medicine, vol. 38, no. 6, pp. 853–858, 1997.

[12] M. Bangard, M. Béhé, S. Guhlke et al., “Detection of somatostatin receptor-positive tumours using the new 99mTc-tricine-HYNIC-D-Phe-Tyr3-octreotide: first results in patients and comparison with 111In-DTPA-D-Phe-octreotide,” European Journal of Nuclear Medicine, vol. 27, no. 6, pp. 628–637, 2000.

[13] J. Kowalski, M. Henze, J. Schuhmacher, H. R. Mäcke, M. Hofmann, and U. Haberkorn, “Evaluation of position emission tomography imaging using $^{68}$Ga-DOTA-D-Phe-Tyr3-octreotide in neuroendocrine tumours,” Molecular Imaging and Biology, vol. 5, no. 1, pp. 42–48, 2003.

[14] I. Buchmann, M. Henze, S. Engelbrecht et al., “Comparison of $^{68}$Ga-DOTATOC PET and $^{111}$In-DTPAOCT (OctreoScan) SPECT in patients with neuroendocrine tumours,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 34, no. 10, pp. 1617–1626, 2007.

[15] M. Hofmann, H. Maecke, A. R. Börner et al., “Biokinetics and imaging with the somatostatin receptor PET radioligand $^{68}$Ga-DOTATOC: preliminary data,” European Journal of Nuclear Medicine, vol. 28, no. 12, pp. 1751–1757, 2001.

[16] D. Wild, J. S. Schmitt, M. Giin et al., “DOTA-NOC, a highaffinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 30, no. 10, pp. 1338–1347, 2003.

[17] V. Ambrosini, D. Campana, L. Bodei et al., “$^{68}$Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumours,” Journal of Nuclear Medicine, vol. 51, no. 5, pp. 669–673, 2010.

[18] P. Antunes, M. Giin, H. Zhang et al., “Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals?” European Journal of Nuclear Medicine and Molecular Imaging, vol. 34, no. 7, pp. 982–993, 2007.

[19] V. Ambrosini, D. Campana, P. Tomassetti, G. Grassetto, D. Rubello, and S. Fanti, “PET/CT with 68gallium-DOTA-peptides in NET: an overview,” European Journal of Radiology, vol. 80, no. 2, pp. e116–e119, 2011.

[20] P. M. Smith-Jones, C. Bischof, M. Leimer et al., “DOTA-NOC, a highaffinity ligand of somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use,” European Journal of Nuclear Medicine, vol. 27, no. 3, pp. 273–282, 2000.

[21] R. C. Walker, G. T. Smith, E. Liu, B. Moore, J. Clanton, and M. Stabin, “Measured human dosimetry of $^{125}$I-Ga-DOTATATE,” Journal of Nuclear Medicine, vol. 54, pp. 853–860, 2013.

[22] H. Hartmann, K. Zopf, R. Freudenberg et al., “Radiation exposure of patients during $^{68}$Ga-DOTATOC PET/CT examinations,” Nuklearmedizin, vol. 48, no. 5, pp. 201–207, 2009.

[23] C. Pettinato, A. Sarnelli, M. Di Donna et al., “$^{68}$Ga-DOTANOC: biodistribution and dosimetry in patients affected by neuroendocrine tumours,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 35, no. 1, pp. 72–79, 2008.

[24] E. P. Krenning, W. H. Bakker, P. P. M. Kooij et al., “Somatostatin receptor scintigraphy with indium-III-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide,” Journal of Nuclear Medicine, vol. 33, no. 5, pp. 652–658, 1992.

[25] R. P. Warner, “Enteroregulatory mechanisms other than carcinoid: a review of clinically significant advances,” Gastroenterology, vol. 128, no. 6, pp. 1668–1684, 2005.

[26] G. L. Cascini, V. Cuccurullo, and L. Mansi, “The non tumour uptake of 111In-octreotide creates new clinical indications in benign diseases, but also in oncology,” Quarterly Journal of Nuclear Medicine and Molecular Imaging, vol. 54, no. 1, pp. 24–36, 2010.
[29] M. C. Smith, M. Maggi, and C. Orlando, “Somatostatin receptors in non-endocrine tumours,” Digestive and Liver Disease, vol. 36, supplement 1, pp. S78–S85, 2004.

[30] I. Virgolini, V. Ambrosini, J. B. Bomanji et al., “Procedure guidelines for PET/CT tumour imaging with 68-Ga-DOTA-conjugated peptides: 68-Ga-DOTA-TOC, 68-Ga-DOTA-NOC, 68-Ga-DOTATATE,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 37, pp. 2004–2010, 2010.

[31] S. Fant, V. Ambrosini, P. Tomassetti et al., “Evaluation of unusual neuroendocrine tumours by means of 68-Ga-DOTA-NOC PET,” Biomedicine and Pharmacotherapy, vol. 62, no. 10, pp. 667–671, 2008.

[32] B. R. Mittal, K. Agrawal, J. Shukla et al., “Ga-68 DOTATATE PET/CT in neuroendocrine tumors: initial experience,” Journal of Postgraduate Medicine Education and Research, vol. 47, pp. 1–6, 2013.

[33] M. Naji, C. Zhao, S. J. Welsh et al., “68-Ga-DOTA-TATE PET vs.123I-MIBG in identifying malignant neural crest tumors,” Molecular Imaging and Biology, vol. 13, no. 4, pp. 769–775, 2011.

[34] Z. Win, L. Rahman, D. Towey, and A. Al-Nahhas, “68-Ga-DOTATATE PET imaging in neuroectodermal tumours,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 33, article S90, 2006.

[35] Z. Win, A. Al-Nahhas, D. Towey et al., “68-Ga-DOTATATE PET in neuroectodermal tumours: first experience,” Nuclear Medicine Communications, vol. 28, no. 5, pp. 359–363, 2007.

[36] A. Kroiss, D. Putzer, C. Uprimny et al., “Functional imaging in pheochromocytoma and neuroblastoma with 68-Ga-DOTA-Tyr3-octreotide positron emission tomography and 123I-metaiodobenzylguanidine,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 38, no. 5, pp. 865–873, 2011.

[37] J. B. Maurice, R. Troke, Z. Win et al., “A comparison of the performance of 68Ga-DOTATATE PET/CT and 123I-MIBG SPECT in the diagnosis and follow-up of pheochromocytoma and paraganglioma,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 39, pp. 1266–1270, 2012.

[38] P. Sharma, A. Thakar, K. C. S. Suman et al., “68Ga-DOTANOC PET/CT for baseline evaluation of patients with head and neck paraganglioma,” Journal of Nuclear Medicine, vol. 54, pp. 841–847, 2013.

[39] M. S. Hofman, G. Kong, O. C. Neels, P. Eu, E. Hong, and R. J. Hicks, “High management impact of Ga-68 DOTATATE (GaTate) PET/CT for imaging neuroendocrine and other somatostatin expressing tumours,” Journal of Medical Imaging and Radiation Oncology, vol. 56, no. 1, pp. 40–47, 2012.

[40] S. Koukouraki, L. G. Strauss, V. Georgoulias, M. Eisenhut, U. Haberkorn, and A. Dimitrakopoulou-Strass, “Comparison of the pharmacokinetics of 68-Ga-DOTATOC and [18F]FDG in patients with metastatic neuroendocrine tumours scheduled for 90-Y-DOTATOC therapy,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 33, no. 10, pp. 1115–1122, 2006.

[41] M. Gabriel, C. Decristoforo, D. Kendler et al., “68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumours: comparison with somatostatin receptor scintigraphy and CT,” Journal of Nuclear Medicine, vol. 48, no. 4, pp. 508–518, 2007.

[42] V. Ambrosini, P. Castellucli, D. Rubello et al., “68Ga-DOTANOC: a new PET tracer for evaluating patients with bronchial carcinoid,” Nuclear Medicine Communications, vol. 30, no. 4, pp. 281–286, 2009.

[43] I. Kayani, B. G. Conry, A. M. Groves et al., “A comparison of 68Ga-DOTATATE and 18F-FDG PET/CT in pulmonary neuroendocrine tumors,” Journal of Nuclear Medicine, vol. 50, no. 12, pp. 1927–1932, 2009.

[44] A. Kumar, T. Jindal, R. Dutta, and R. Kumar, “Functional imaging in differentiating bronchial masses: an initial experience with a combination of 18F-FDG PET-CT scan and 68Ga-DOTATOC PET-CT scan,” Annals of Nuclear Medicine, vol. 23, no. 8, pp. 745–751, 2009.

[45] T. Jindal, A. Kumar, B. Venkitaraman et al., “Evaluation of the role of [18F]FDG PET/CT and [68Ga]DOTATOC PET/CT in differentiating typical and atypical pulmonary carcinoids,” Cancer Imaging, vol. 11, no. 1, pp. 70–75, 2011.

[46] T. Jindal, A. Kumar, B. Venkitaraman, R. Dutta, and R. Kumar, “Role of 68-Ga-DOTATOC PET/CT in the evaluation of primary pulmonary carcinoids,” Korean Journal of Internal Medicine, vol. 25, no. 4, pp. 386–391, 2010.

[47] D. Putzer, A. Kroiss, D. Waizt et al., “Somatostatin receptor PET in neuroendocrine tumours: 68Ga-DOTA0, Tyr3-octreotide versus 68-Ga-DOTA0-lanreotide,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 40, pp. 364–372, 2013.

[48] V. Ambrosini, C. Nanni, M. Zompatori et al., “68Ga-DOTANOC PET/CT in comparison with CT for the detection of bone metastasis in patients with neuroendocrine tumours,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 37, no. 4, pp. 722–727, 2010.

[49] D. Putzer, M. Gabriel, B. Henninger et al., “Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy,” Journal of Nuclear Medicine, vol. 50, no. 8, pp. 1214–1221, 2009.

[50] A. R. Haug, C. J. Auernhammer, B. Wängler et al., “68Ga-DOTATATE PET/CT for the early prediction of response to somatostatin receptor-mediated radio nuclide therapy in patients with well-differentiated neuroendocrine tumors,” Journal of Nuclear Medicine, vol. 51, no. 9, pp. 1349–1356, 2010.

[51] A. Dimitrakopoulou-Strass, V. Georgoulias, M. Eisenhut et al., “Quantitative assessment of SSTR2 expression in patients with non-small cell lung cancer using 68Ga-DOTATOC PET and comparison with 18F-FDG PET,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 33, no. 7, pp. 823–830, 2006.

[52] M. Sollini, D. Farioli, A. Froio et al., “Brief report on the use of radiolabeled somatostatin analogs for the diagnosis and treatment of metastatic small-cell lung cancer patients,” Journal of Thoracic Oncology, vol. 8, pp. 1095–1101, 2013.

[53] D. Waizt, D. Putzer, H. Kostron, and I. J. Virgolini, “Treatment of high-grade glioma with radiolabeled peptides,” Methods, vol. 55, no. 3, pp. 223–229, 2011.

[54] D. Heute, H. Kostron, E. Von Guggenberg et al., “Response of recurrent high-grade glioma to treatment with 90Y-DOTATOC,” Journal of Nuclear Medicine, vol. 51, no. 3, pp. 397–400, 2010.

[55] J. E. Gains, J. B. Bomanji, N. L. Fersht et al., “177Lu-DOTATATE molecular radiotherapy for childhood neuroblastoma,” Journal of Nuclear Medicine, vol. 52, no. 7, pp. 1041–1047, 2011.

[56] A. Afshar-Oromieh, F. L. Giesel, H. G. Linhart et al., “Detection of cranial meningiomas: comparison of Ga-DOTATOC PET/CT and contrast-enhanced MRI,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 39, pp. 1409–1415, 2012.

[57] S. Milker-Zabel, A. Zabel-du Bois, M. Henze et al., “Improved target volume definition for fractionated stereotactic radiotherapy in patients with intracranial meningiomas by correlation of
[58] B. Gehler, F. Paulsen, M. T. Öksüz et al., “[68Ga]DOTATOC-PET/CT for meningioma IMRT treatment planning,” Radiation Oncology, vol. 4, no. 1, article 56, 2009.

[59] F. Nyuyki, M. Plotkin, R. Graf et al., “Potential impact of 68 Ga-DOTATOC PET/CT on stereotactic radiotherapy planning of meningiomas,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 37, no. 2, pp. 310–318, 2010.

[60] R. Graf, M. Plotkin, I. G. Steffen et al., “Magnetic resonance imaging, computed tomography, and 68 Ga-DOTATOC positron emission tomography for imaging skull base meningiomas with infracranial extension treated with stereotactic radiotherapy—a case series,” Head and Face Medicine, vol. 8, no. 1, article 1, 2012.

[61] H. Hänscheid, R. A. Sweeney, M. Flentje et al., “PET SUV correlates with radionuclide uptake in peptide receptor therapy in meningioma,” European Journal of Nuclear Medicine, vol. 39, pp. 1284–1288, 2012.

[62] B. G. Conry, N. D. Papathanasiou, V. Prakash et al., “Comparison of 68 Ga-DOTATATE and 18 F-fluorodeoxyglucose PET/CT in the detection of recurrent medullary thyroid carcinoma,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 37, no. 1, pp. 49–57, 2010.

[63] G. Treglia, P. Castaldi, M. F. Villani et al., “Comparison of 18 F-DOPA, 18 F-FDG and 68 Ga-somatostatin analogue PET/CT in patients with recurrent medullary thyroid carcinoma,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 39, pp. 569–580, 2012.

[64] M. Middendorp, I. Selkisni, C. Happel, W. T. Kranert, and F. Grünwald, “Comparison of positron emission tomography with [18F]FDG and [68Ga]DOTATOC in recurrent differentiated thyroid cancer: preliminary data,” Quarterly Journal of Nuclear Medicine and Molecular Imaging, vol. 54, no. 1, pp. 76–83, 2010.

[65] M. Gabriel, U. Andergassen, D. Putzer et al., “Individualized peptide-related-radionuclide-therapy concept using different radiolabelled somatostatin analogs in advanced cancer patients,” Quarterly Journal of Nuclear Medicine and Molecular Imaging, vol. 54, no. 1, pp. 92–99, 2010.

[66] A. Versari, M. Sollini, A. Frasoldati et al., “Differentiated thyroid cancer: a new perspective with radiolabeled somatostatin analogues for imaging and treatment of patients,” Thyroid. In press.

[67] J. Vasamitilie, P. Hohenberger, S. Schoenberg et al., “Treatment monitoring with 18F-FDG PET in metastatic thymoma after 90Y-Dotatoc and selective internal radiation treatment (SIRT),” Hellenic Journal of Nuclear Medicine, vol. 12, no. 3, pp. 271–309, 2009.

[68] R. Dutta, A. Kumar, P. K. Jukla et al., “Thymic neuroendocrine tumour (carcinoid): clinicopathological features of four patients with different presentation,” Interactive Cardiovascular and Thoracic Surgery, vol. 11, no. 6, pp. 732–736, 2010.

[69] A. Froio, M. Sollini, A. Fraternali et al., “Thymic neoplasms evaluation: role of 68Ga-peptide and [18F]FDG PET/CT,” Journal of Nuclear Medicine, vol. 54, no. 5, supplement 1, article 1632, 2013.

[70] C. Schneider, M. Schlaak, M. Bludau, B. Markielka, and M. C. Schmidt, “68 Ga-DOTATATE-PET/CT positive metastatic lymph node in a 69-year-old woman with Merkel cell carcinoma,” Clinical Nuclear Medicine, vol. 37, pp. 1108–1111, 2012.

[71] M. C. Schmidt, K. Uhrban, B. Markielka et al., “68 Ga-DotaTATE PET-CT followed by Peptide Receptor Radiotherapy in combination with capetitabine in two patients with Merkel Cell Carcinoma,” International Journal of Clinical and Experimental Medicine, vol. 5, pp. 363–366, 2012.

[72] R. Dutta, A. Kumar, P. K. Jukla et al., “Thymic neuroendocrine tumour (carcinoid): clinicopathological features of four patients with different presentation,” Interactive Cardiovascular and Thoracic Surgery, vol. 11, no. 6, pp. 732–736, 2010.

[73] A. Froio, M. Sollini, A. Fraternali et al., “Thymic neoplasms evaluation: role of 68Ga-peptide and [18F]FDG PET/CT,” Journal of Nuclear Medicine, vol. 54, no. 5, supplement 1, article 1632, 2013.

[74] C. Schneider, M. Schlaak, M. Bludau, B. Markielka, and M. C. Schmidt, “68 Ga-DOTATATE-PET/CT positive metastatic lymph node in a 69-year-old woman with Merkel cell carcinoma,” Clinical Nuclear Medicine, vol. 37, pp. 1108–1111, 2012.

[75] M. Epstude, K. Tornquist, C. Riklin et al., “Comparison of 18F-FDG PET/CT and (68)Ga-DOTATATE PET/CT imaging in metastasized merkel cell carcinoma,” Clinical Nuclear Medicine, vol. 38, pp. 283–284, 2013.

[76] F. Elgeti, H. Amthauer, T. Denecke et al., “Incidental detection of breast cancer by 68 Ga-DOTATOC-PET/CT in women suffering from neuroendocrine tumours,” Nuklearmedizin, vol. 47, no. 6, pp. 261–265, 2008.

[77] C. Casini Raggi, A. Calabrò, D. Renzi et al., “Quantitative evaluation of somatostatin receptor subtype 2 expression in sporadic colorectal tumor and in the corresponding normal mucosa,” Clinical Cancer Research, vol. 8, no. 2, pp. 419–427, 2002.

[78] A. Haug, R. Cindea-Drimus, C. Auernhammer, G. Schmidt, P. Bartenstein, and M. Hacker, “68 Ga-DOTATATE PET/CT in the diagnosis of recurrent neuroendocrine tumors,” Journal of Nuclear Medicine, vol. 53, supplement 1, article 419, 2012.

[79] K. Desai, J. Watkins, N. Woodward et al., “Use of molecular imaging to differentiate liver metastasis of colorectal cancer metastasis from neuroendocrine tumor origin,” Journal of Clinical Gastroenterology, vol. 45, no. 1, pp. e8–e11, 2011.

[80] C. Brogsitter, K. Zöphel, G. Wunderlich, E. Kämmerer, A. Stein, and J. Kotzerke, “Comparison between F-18 fluorodeoxyglucose and Ga-68 DOTATOC in metastasized melanoma,” Nuclear Medicine Communications, vol. 34, pp. 47–49, 2013.

[81] M. Souvatzoglou, T. Maurer, U. Treiber, G. Weirich, B. J. Krause, and M. Essler, “68 Ga-DOTATOC-PET/CT detects neuroendocrine differentiation of prostate cancer metastases,” Nuklearmedizin, vol. 48, no. 5, pp. N52–N54, 2009.

[82] W. Luboldt, K. Zöphel, G. Wunderlich, A. Abramuyk, H.-J. Luboldt, and J. Kotzerke, “Visualization of somatostatin receptors in prostate cancer and its bone metastases with Ga-68-DOTATOC PET/CT,” Molecular Imaging and Biology, vol. 12, no. 1, pp. 78–84, 2010.
[85] O. Alonso, J. P. Gambini, G. Lago, J. Gaudiano, A. Quagliata, and H. Engler, "In vivo visualization of somatostatin receptor expression with Ga-68-DOTA-TATE PET/CT in advanced metastatic prostate cancer," *Clinical Nuclear Medicine*, vol. 36, no. 11, pp. 1063–1064, 2011.

[86] C. Von Falck, T. Rodt, H. Rosenthal et al., "68-Ga-DOTANOC PET/CT for the detection of a mesenchymal tumor causing oncogenic osteomalacia," *European Journal of Nuclear Medicine and Molecular Imaging*, vol. 35, no. 5, article 1034, 2008.

[87] E. Woff, C. Garcia, L. Tant et al., "Imaging of tumour-induced osteomalacia using a gallium-68 labelled somatostatin analogue," *BMJ Case Reports*, vol. 2010, Article ID bcr0220102750, 2010.

[88] R. J. Clifton-Bligh, M. S. Hofman, E. Duncan et al., "Improving diagnosis of tumor-induced osteomalacia with Gallium-68 DOTATATE PET/CT," *The Journal of Clinical Endocrinology & Metabolism*, vol. 98, pp. 687–694, 2013.

[89] C. Mawrin, S. Schulz, S. U. Pauli et al., "Differential expression of ssl, sst2A, and sst3 somatostatin receptor proteins in low-grade and high-grade astrocytomas," *Journal of Neuropathology and Experimental Neurology*, vol. 63, no. 1, pp. 13–19, 2004.

[90] U. Kumar, S. I. Grigorakis, H. L. Watt et al., "Somatostatin receptors in primary human breast cancer: quantitative analysis of mRNA for subtypes 1–5 and correlation with receptor protein expression and tumor pathology," *Breast Cancer Research and Treatment*, vol. 92, no. 2, pp. 175–186, 2005.

[91] C.-Z. Qiu, S.-Z. Zhu, Y.-Y. Wu, C. Wang, Z.-X. Huang, and J.-L. Qiu, "Relationship between somatostatin receptor subtype expression and clinicopathology, Ki-67, Bcl-2 and p53 in colorectal cancer," *World Journal of Gastroenterology*, vol. 12, no. 13, pp. 2011–2015, 2006.

[92] K. Pazaitou-Panayiotou, E. Tiensuu Janson, T. Koletsa et al., "Somatostatin receptor expression in non-medullary thyroid carcinomas," *Hormones (Athens)*, vol. 11, pp. 290–296, 2012.

[93] K. Szepehazi, A. V. Schally, A. Nagy, B. W. Wagner, A. M. Bajo, and G. Halmos, "Preclinical evaluation of therapeutic effects of targeted cytotoxic analogs of somatostatin and bombesin on human gastric carcinomas," *Cancer*, vol. 98, no. 7, pp. 1401–1410, 2003.

[94] J. C. Reubi, B. Waser, J.-C. Schaer, and J. A. Laisse, "Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands," *European Journal of Nuclear Medicine*, vol. 28, no. 7, pp. 836–846, 2001.

[95] G. Palmieri, L. Montella, C. Aiello et al., "Somatostatin analogues, a series of tissue transglutaminase inducers, as a new tool for therapy of mesenchimal tumors of the gastrointestinal tract," *Amino Acids*, vol. 32, no. 3, pp. 395–400, 2007.

[96] T. Florio, L. Montella, A. Corsaro et al., "In vitro and in vivo expression of somatostatin receptors in intermediate and malignant soft tissue tumors," *Anticancer Research*, vol. 23, no. 3, pp. 2465–2471, 2003.

[97] M. Bläker, M. Schmitz, A. Gocht et al., "Differential expression of somatostatin receptor subtypes in hepatocellular carcinomas," *Journal of Hepatology*, vol. 41, no. 1, pp. 112–118, 2004.

[98] V. A. S. H. Dalm, L. J. Hofland, C. M. Mooy et al., "Somatostatin receptors in malignant lymphomas: targets for radiotherapy?" *Journal of Nuclear Medicine*, vol. 45, no. 1, pp. 8–16, 2004.

[99] S. S. Lum, W. S. Fletcher, M. S. O’Dorisio, R. W. Nance, R. F. Pommier, and M. Caprara, "Distribution and functional significance of somatostatin receptors in malignant melanoma," *World Journal of Surgery*, vol. 25, no. 4, pp. 407–412, 2001.

[100] S. Arena, F. Barbieri, S. Thellung et al., "Expression of somatostatin receptor mRNA in human meningiomas and their implication in in vitro antiproliferative activity," *Journal of Neuro-Oncology*, vol. 66, no. 1-2, pp. 153–166, 2004.

[101] M. Papotti, L. Macri, A. Pagani, F. Aloj, and G. Bussolati, "Quantification of somatostatin receptor type 2 in neuroendocrine (Merkel cell) carcinoma of the skin by competitive RT-PCR," *Endocrine Pathology*, vol. 10, no. 1, pp. 37–46, 1999.

[102] M. C. Zatelli, F. Tagliati, J. E. Taylor, R. Rossi, M. D. Culler, and E. C. Degli Uberti, "Somatostatin receptor subtypes 2 and 5 differentially affect proliferation in vitro of the human medullary thyroid carcinoma cell line TT," *Journal of Clinical Endocrinology and Metabolism*, vol. 86, no. 5, pp. 2161–2169, 2001.

[103] E. Mato, X. Matias-Guiu, A. Chico et al., "Somatostatin and somatostatin receptor subtype gene expression in medullary thyroid carcinoma," *Journal of Clinical Endocrinology and Metabolism*, vol. 83, no. 7, pp. 2417–2420, 1998.

[104] D. Ferone, M. Arvigo, C. Semino et al., "Somatostatin and dopamine receptor expression in lung carcinoma cells and effects of chimeric somatostatin-dopamine molecules on cell proliferation," *American Journal of Physiology—Endocrinology and Metabolism*, vol. 289, no. 6, pp. E1044–E1050, 2005.

[105] N. Dizeyi, L. Konrad, A. Bjartell et al., "Localization and mRNA expression of somatostatin receptor subtypes in human prostate tissue and prostate cancer cell lines," *Urologic Oncology*, vol. 7, no. 3, pp. 91–98, 2002.

[106] E. Kosari, J. M. A. Munz, C. D. Savi-Hejjink et al., "Identification of prognostic biomarkers for prostate cancer," *Clinical Cancer Research*, vol. 14, no. 6, pp. 1734–1743, 2008.

[107] A. Saveanu and P. Jaquet, "Somatostatin–dopamine ligands in the treatment of pituitary adenomas," *Reviews in Endocrine and Metabolic Disorders*, vol. 10, no. 2, pp. 83–90, 2009.

[108] T. Tateno, M. Kato, Y. Tani, K. Oyama, S. Yamada, and Y. Hirata, "Differential expression of somatostatin and dopamine receptor subtype genes in adenocorticotropin (ACTH)-secreting pituitary tumors and silent corticotroph adenomas," *Endocrine Journal*, vol. 56, no. 4, pp. 579–584, 2009.

[109] A. Fusco, G. Gunz, P. Jaquet et al., "Somatostatinergic ligands in dopamine-sensitive and -resistant prolactinomas," *European Journal of Endocrinology*, vol. 158, no. 3, pp. 395–603, 2008.

[110] A. Yoshihara, O. Isozaki, N. Hizuka et al., "Expression of type 5 somatostatin receptor in TSH-secreting pituitary adenomas: a possible marker for predicting longterm response to octreotide therapy," *Endocrine Journal*, vol. 54, no. 1, pp. 133–138, 2007.

[111] A. Saveanu, I. Morange-Ramos, G. Gunz, H. Dufour, A. Enjalbert, and P. Jaquet, "A luteinizing hormone-, alpha-subunit- and prolactin-secreting pituitary adenoma responsive to somatostatin analogs, BIM-23A760, in the control of cell growth from primary cultures of human non-functioning pituitary adenomas: A Multi–Center Study," *Endocrine-Related Cancer*, vol. 15, no. 2, pp. 583–596, 2008.